Pharmaceutical Business review

Plethico acquires Natrol

The acquisition was completed in accordance with the merger agreement announced earlier among Plethico, Nutra Acquisition Company (MergerSub), a wholly owned subsidiary of Plethico, and Natrol, by means of the merger of Natrol with MergerSub following a successful tender offer for Natrol’s common shares.

In the merger, all outstanding shares of Natrol common stock were converted into the right to receive $4.40 net per share in cash, without interest thereon and less any required withholding taxes (the same price as the offer price in MergerSub’s tender offer).

Shashikant Patel, chairman and managing director of Plethico, said: “We are pleased to announce the successful completion of Plethico’s acquisition of Natrol, and we are excited with the opportunity this acquisition represents for Plethico.”